Clinical Trial: A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07808827) titled 'A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma' on Sept. 02.

Brief Summary: This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (JS203-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.

Study Start Date: Sept. 24

Study Type: INTERVENTIONAL

Condition: Diffuse Large B-Cell Lymphoma

Intervention: COMBINATION_PRODUCT: JS203 in combination with gemcitabine and oxa...